Kazuyoshi Ohkawa

11PUBLICATIONS
29CO-AUTHORS
Predictive and prognostic markersChemotherapyRespiratory diseasesCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 24, 2024
Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study.

Kazuyoshi Ohkawa, Tasuku Nakabori, Kaori Mukai

|Jul 26, 2024
A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy.

Junji Furuse, Masafumi Ikeda, Makoto Ueno

|Feb 24, 2023
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).

Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita

|Dec 12, 2022
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.

Yuki Tahata, Ryotaro Sakamori, Kazuki Maesaka

|Jun 24, 2022
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.

Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada

|Apr 13, 2022
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.

Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada

Pageof 2

Frequent Collaborators

8 joint publications

Ryotaro Sakamori

8 joint publications

Tetsuo Takehara

7 joint publications

Takahiro Kodama

7 joint publications

Hayato Hikita